Pablo Martinez is an accomplished professional in the field of oncology and drug development, currently serving as Executive Director of Late Development and Program Lead, as well as Executive Director of Early Development at Amgen. Previously, Pablo held the position of Senior Director of Translational Medicine at Sumitomo Dainippon Pharma Oncology and served as Director and Associate Director of Early Drug Development at AstraZeneca. Early career experience includes a role as Clinical Research Fellow at Dana-Farber Cancer Institute and Clinical Oncology Specialist at Vall d´Hebron Institute of Oncology. Pablo's educational background includes a Postdoctoral Fellowship in Oncology and Cancer Biology from Harvard University and a Master of Science in Immunology from Universitat de Barcelona.